Irinotecan Hydrochloride Injection
Product Images NDC 72485-211

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 72485-211). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Fig3)

This is a figure (Figure 3) showing survival probability for second-line treatment with Irinotecan compared to best supportive care in a study (Study 7). It includes data on the number of patients (N), median follow-up time in months, and median survival in months for both treatments. The *log-rank test was used.*

FDA Label Image

Image Description (Fig4)

FDA Label Image

Image Description (Label1.2)

This is a description of a medication called Irinotecan, which is a cytotoxic agent used for intravenous injection. Each mL contains 20 mg of irinotecan hydrochloride, USP, 45 mg of sonvitol [rinotecan Hydrochloride powder, and other ingredients. The dosage information for the medication should be obtained from the accompanying prescribing information. The product is manufactured by Shilpa Medicare Limited in India and distributed by Armas Pharmaceuticals in the USA. It comes in a single-dose vial of 2 mL, and any unused portion should be discarded. The medication should be stored at 20° to 25°C (68° to 77°F), protected from light and freezing.*

FDA Label Image

Image Description (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.